151751-Najiba-Chargi

308 CHAPTER 16 REFERENCES 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer sta - tistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/ caac.21492 [doi]. 2. Argiris A, Eng C. Epidemiology, staging, and screening of head and neck cancer. Cancer Treat Res. 2003; 114:15-60. 3. Hashibe M, Brennan P, Chuang SC, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: Pooled analysis in the international head and neck cancer epidemiology consor- tium. Cancer Epidemiol Biomarkers Prev. 2009;18(2):541-550. doi: 10.1158/1055- 9965.EPI-08-0347 [doi]. 4. Mehanna H, Beech T, Nicholson T, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer--systematic review and meta-analysis of trends by time and region. Head Neck. 2013;35(5):747-755. doi: 10.1002/hed.22015 [doi]. 5. Windon MJ, D’Souza G, Rettig EM, et al. In - creasing prevalence of human papillomavi- rus-positive oropharyngeal cancers among older adults. Cancer. 2018;124(14):2993- 2999. doi: 10.1002/cncr.31385 [doi]. 6. Anantharaman D, Billot A, Waterboer T, et al. Predictors of oropharyngeal cancer sur - vival in europe. Oral Oncol. 2018;81:89-94. doi: S1368-8375(18)30158-1 [pii]. 7. Habbous S, Harland LT, La Delfa A, et al. Co - morbidity and prognosis in head and neck cancers: Differences by subsite, stage, and human papillomavirus status. Head Neck. 2014;36(6):802-810. doi: 10.1002/hed.23360 [doi]. 8. Le Tourneau C, Velten M, Jung GM, Bronner G, Flesch H, Borel C. Prognostic indicators for survival in head and neck squamous cell carcinomas: Analysis of a series of 621 cases. Head Neck. 2005;27(9):801-808. doi: 10.1002/hed.20254 [doi]. 9. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24-35. doi: 10.1056/ NEJMoa0912217 [doi]. 10. Dahlstrom KR, Garden AS, William WN,Jr, Lim MY, Sturgis EM. Proposed staging system for patients with HPV-related oro - pharyngeal cancer based on nasopha- ryngeal cancer N categories. J Clin Oncol. 2016;34(16):1848-1854. doi: 10.1200/ JCO.2015.64.6448 [doi]. 11. Huang SH, Xu W, Waldron J, et al. Refining american joint committee on cancer/union for international cancer control TNM stage and prognostic groups for human papillo- mavirus-related oropharyngeal carcino- mas. J Clin Oncol. 2015;33(8):836-845. doi: 10.1200/JCO.2014.58.6412 [doi]. 12. O’Sullivan B1, Huang SH, Siu LL, Waldron J, Zhao H, Perez-Ordonez B, Weinreb I, Kim J, Ringash J, Bayley A, Dawson LA, Hope A, Cho J, Irish J, Gilbert R, Gullane P, Hui A, Liu FF, Chen E, Xu W. Deintensification candidate subgroups in human papilloma- virus-related oropharyngeal cancer accord- ing to minimal risk of distant metastasis. J Clin Oncol. :50. 13. Daly LE, Prado CM, Ryan AM. A window be - neath the skin: How computed tomography assessment of body composition can assist in the identification of hidden wasting con- ditions in oncology that profoundly impact outcomes. Proc Nutr Soc. 2018;77(2):135- 151. doi: 10.1017/S0029665118000046 [doi].